STAT+: Pharmalittle: We’re reading about TrumpRx shortcomings, Lilly targeting employers, and more

Medical Developments and Setbacks: A Week in Review
SUBTITLE: From TrumpRx shortcomings to breakthroughs in Alzheimer's treatment and allergy awareness
EXCERPT: A mixed bag of medical developments saw TrumpRx's limited drug availability, a major funding boost for an Alzheimer's treatment device, and compulsory allergy training in English schools.

A month after its launch, TrumpRx, the website aimed at making prescription medication more affordable, has been criticized for its limited availability of drugs. Meanwhile, Cognito, a company working on an Alzheimer's treatment device, raised $105 million in funding, awaiting trial data to convince the FDA to authorize its product. In the UK, schools in England will now be required to provide allergy awareness training for all staff, and spare adrenaline auto-injectors must be stocked for emergencies.

What Happened

• TrumpRx, launched with the aim of making prescription medication more affordable, has been found to have limited drug availability, with data about its usage remaining unknown.
• Cognito raised $105 million in funding for its Alzheimer's treatment device, awaiting trial data to convince the FDA to authorize its product.
• Schools in England will now be required to provide allergy awareness training for all staff, and spare adrenaline auto-injectors must be stocked for emergencies.

Why It Matters

The developments in the medical field this week highlight both the progress and the challenges faced in improving healthcare. TrumpRx's shortcomings underscore the need for more comprehensive solutions to make prescription medication affordable. On the other hand, Cognito's funding boost brings hope for a breakthrough in Alzheimer's treatment. The compulsory allergy training in English schools is a step towards ensuring the safety of children with severe allergies.

What Experts Say

> "On behalf of the trust, I offer my unreserved apologies for the failings in Jack's care." — Dr. Sue Broster, Cambridge University Hospitals NHS Foundation Trust

Key Numbers

• 8 million: The number of HIV-positive people in South Africa, the highest in the world.
• $105 million: The amount raised by Cognito for its Alzheimer's treatment device.
• 1 in 5: The proportion of adults in South Africa living with HIV.
• 42%: The percentage of schools in England that already have great policies in place for allergy awareness.

Background

The need for affordable prescription medication and effective treatments for diseases like Alzheimer's and HIV is pressing. The developments this week highlight the ongoing efforts to address these challenges. In the case of TrumpRx, its limited drug availability is a setback, but Cognito's funding boost offers hope for a breakthrough in Alzheimer's treatment. The compulsory allergy training in English schools is a step towards ensuring the safety of children with severe allergies.

What Comes Next

As the medical field continues to evolve, it is crucial to address the challenges and build on the progress made. The implications of TrumpRx's shortcomings, Cognito's funding boost, and the compulsory allergy training in English schools will be closely watched in the coming weeks.